Sections 15. The School board will provide discounted rates for all employees. Additionally, the ad hoc committee established in 2008/09 will continue to meet and evaluate the current Extended Day Care Program and make recommendations as necessary. See Appendix G.
Sections 15. The School board will provide discounted rates for all employees. Additionally, the ad hoc committee established in 2008/09 will continue to meet and evaluate the current KidZone and Beyond Program and make recommendations as necessary. See Appendix G.
Sections 15. 2(a)-(b) of the Amended and Restated Agreement are hereby restated in their entirety as follows:
Sections 15. 1 (Addresses and Notices) and 15.2 (Further Action) of the Operating Agreement are deemed incorporated into this Subscription Agreement.
Sections 15. 2 and 15.3 of the MSA shall be deemed to be incorporated herein by reference (mutatis mutandis) and shall be deemed to apply both (i) with respect to the Parties’ performance of their respective obligations under this Transition Agreement from and after the Effective Date and (ii) with respect to the information obtained by each Party during the term of the MSA.
Sections 15. 1 through 15.4 of this Lease are deleted in their entirety and the following is substituted in lieu thereof:
Sections 15. 14. (Governing Law) and 15.15. (Jurisdiction; Venue, Dispute Resolution) shall apply also to this Amendment. HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. EXECUTION COPY IN WITNESS WHEREOF, the Parties, through their authorized representatives, have executed two (2) identical counterparts of this Amendment. RECRO PHARMA, INC. By: /s/ Xxxxx Xxxxxxx Name: Xxxxx Xxxxxxx Title: CEO ORION CORPORATION By: /s/ Pekka Kanola By: /s/ Xxxxx Xxxxx Name: Pekka Kanola Name: Xxxxx Xxxxx Title: SVP/Sales Title: Senior Vice President CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. EXECUTION COPY Appendix 1 Development and Commercialization [* * *] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. EXECUTION COPY This Schedule shall be attached as Appendix 1 to that certain Amendment 1 to the License Agreement between Orion Corporation and Recro Pharma, Inc. dated as of August 22, 2008 and is incorporated by reference into and made a part of such Agreement. RECRO PHARMA, INC. ORION CORPORATION By: /s/ Xxxxx Xxxxxxx By: /s/ Pekka Kanola Name: Xxxxx Xxxxxxx Name: Pekka Kanola Title: CEO Title: SVP/Sales By: /s/ Xxxxx Xxxxx Name: Xxxxx Xxxxx
Sections 15. 02.3 and 15.03 shall not apply to ownership by Master Licensor of any interest in a System store or of less than five percent (5%) beneficial interest in the outstanding equity securities of any publicly-held corporation.
Sections 15. 1.1 and 15.1.2 of the Golf JV Agreement and Sections 14.1.1 and 14.1.2 of the Commercial JV Agreement (each of which relates to restrictions on transfers) shall apply to Emerald in the same manner as if “Xxxxx X. Xxxxx” were substituted for “Xxxx X. Xxxxxxxx” and if “Emerald” were substituted for “AVG” or “AVC” each place they appear.
Sections 15. A. through 15.D. of the Loan Agreement are hereby deleted in their entirety and the following sections substituted therefor:
